|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61K 31/575 | (2006.01) |
| A61P 21/00 | (2006.01) | ||
| A61P 19/02 | (2006.01) | ||
| A61P 11/06 | (2006.01) |
| (11) | Number of the document | 2805720 |
| (13) | Kind of document | T |
| (96) | European patent application number | 14173342.8 |
| Date of filing the European patent application | 2009-05-28 | |
| (97) | Date of publication of the European application | 2014-11-26 |
| (45) | Date of publication and mention of the grant of the patent | 2019-08-07 |
| (46) | Date of publication of the claims translation | 2019-09-25 |
| (30) | Number | Date | Country code |
| 56715 P | 2008-05-28 | US |
| (72) |
Mccall, John, M., US
Hoffman, Eric, US
Kanneboyina, Nagaraju, US
|
| (73) |
ReveraGen BioPharma, Inc.,
155 Gibbs Street, Suite 433, Rockville, MD 20850,
US
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Nehormoniniai steroidiniai NF-KB moduliatoriai, skirti ligoms gydyti |
| Non-hormonal steroid modulators of NF-KB for treatment of disease |
| Payment date | Validity (years) | Amount | |
| 2025-06-02 | 17 | 520.50 EUR |
| 2026-05-28 |